公开(公告)号：US20220204507A1

公开(公告)日：2022-06-30

申请号：US17600994

申请日：2020-04-03

申请人： GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY ,  MEDSHINE DISCOVERY INC.

发明人： Jiansong WANG ,  Zhifei FU ,  Zhibo LUO ,  Miaorong LUO ,  Yang ZHANG ,  Yalei CAI ,  Wu ZHU ,  Jian LI ,  Shuhui CHEN ,  Yingxia BAO ,  Wei WANG ,  Zhoufan XIE

IPC分类号： C07D471/10 ,  A61P35/00 ,  C07D401/14 ,  C07D413/14 ,  C07D498/10

摘要： Disclosed are a series of compounds with a nitrogen-containing spiro structure and an application thereof in the preparation of an RET kinase inhibitor. Specifically, disclosed is a compound as shown in formula (II) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240238281A1

公开(公告)日：2024-07-18

申请号：US18557580

申请日：2022-04-22

申请人： GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY ,  MEDSHINE DISCOVERY INC.

发明人： Jiansong WANG ,  Zhibo LUO ,  Fei QIN ,  Wei WEI ,  Zhigan JIANG ,  Zhixiang PAN ,  Yingxia BAO ,  Haiying HE ,  Haiwen HUANG ,  Shuhui CHEN

IPC分类号： A61K31/496 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14

CPC分类号： A61K31/496 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14

摘要： A class of piperazine derivatives and application thereof, specifically compound represented by formula (III) or pharmaceutically acceptable salt thereof.

公开(公告)号：US20230312504A1

公开(公告)日：2023-10-05

申请号：US17800609

申请日：2021-02-19

申请人： Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory

发明人： Jiansong WANG ,  Yang ZHANG ,  Zhibo LUO ,  Rongxin HUANG ,  Jikui SUN ,  Jie LI ,  Wentao WU ,  Jian LI ,  Shuhui CHEN ,  Yingxia BAO ,  Wei WANG ,  Zhoufan XIE

IPC分类号： C07D401/04 ,  C07D405/14 ,  C07D471/08

CPC分类号： C07D401/04 ,  C07D471/08 ,  C07D405/14

摘要： Disclosed are a class of compounds represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

公开(公告)号：US20230365596A1

公开(公告)日：2023-11-16

申请号：US18246893

申请日：2021-09-26

申请人： GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY

发明人： Jiansong WANG ,  Zhifei FU ,  Zhibo LUO ,  Miaorong LUO ,  Yang ZHANG ,  Jian LI ,  Shuhui CHEN ,  Yingxia BAO ,  Wei WANG ,  Zhoufan XIE

IPC分类号： C07D519/00 ,  A61P35/00

CPC分类号： C07D519/00 ,  A61P35/00 ,  C07B2200/13

摘要： Provided are crystal forms of compounds represented by formula(II)-formula (VIII) and formula (I)-formula (VIII-1), a preparation method therefor and an application of the compounds and crystal forms in the preparation of a drug for treating a related disease.

公开(公告)号：US20220220104A1

公开(公告)日：2022-07-14

申请号：US17600900

申请日：2020-04-03

申请人： GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY ,  MEDSHINE DISCOVERY INC.

发明人： Jiansong WANG ,  Zhengxia CHEN ,  Zhibo LUO ,  Meibi DAI ,  Yang ZHANG ,  Shuhui CHEN ,  Yingxia BAO ,  Wei WANG ,  Zhoufan XIE

IPC分类号： C07D471/04 ,  C07D519/00 ,  C07D491/04 ,  A61P35/00

摘要： Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10251854B2

公开(公告)日：2019-04-09

申请号：US15508761

申请日：2013-07-05

申请人： Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory ,  Guangzhou Institute of Respiratory Disease

发明人： Mao Chen ,  Shaoxuan Zhu ,  Ping Wan ,  Wei Wang ,  Wei Liao ,  Hairong Hu ,  Xianglin Fu ,  Jin Feng ,  Binge Huang ,  Lin Zhang ,  Nanshan Zhong ,  Jinping Zheng ,  Hongying Mo

IPC分类号： A61K31/198 ,  C07C323/58 ,  C07C319/28 ,  C07C319/14

摘要： Disclosed are an S-(carboxymethyl)-cysteine pharmaceutical compound (I), and a preparation method and use thereof. Also disclosed are an S-(carboxymethyl)-D-cysteine ammonium salt monohydrate, and use thereof in preparation of medicines for preventing and treating respiratory system diseases such as chronic obstructive pulmonary diseases, in particular in preparation of expectorants. The compounds can reduce airway resistance and production of oxides in rat COPD models, increase the level of antioxidants, and alleviate damage caused by the oxides and inflammatory mediators to lungs.